Can a year of immunotherapy stop kidney cancer from spreading after radiation?
NCT ID NCT06004336
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests whether adding 1 year of pembrolizumab (an immunotherapy drug) after radiation therapy can better control kidney cancer that has spread to a few spots. About 144 people with this type of cancer will take part. The main goal is to see if the combination is safe and helps prevent the cancer from growing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States